Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 544

1.

Reply to Vena, et al.

Pogue JM, Kaye KS, Bonomo RA, Perez F.

Clin Infect Dis. 2020 Jan 6. pii: ciaa004. doi: 10.1093/cid/ciaa004. [Epub ahead of print] No abstract available.

PMID:
31904808
2.

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

Niederman MS, Alder J, Bassetti M, Boateng F, Cao B, Corkery K, Dhand R, Kaye KS, Lawatscheck R, McLeroth P, Nicolau DP, Wang C, Wood GC, Wunderink RG, Chastre J.

Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30574-2. doi: 10.1016/S1473-3099(19)30574-2. [Epub ahead of print]

PMID:
31866328
3.

Collaborative Antimicrobial Stewardship: Working with Hospital and Health System Administration.

Buckel WR, Kaye KS, Patel PK.

Infect Dis Clin North Am. 2020 Mar;34(1):1-15. doi: 10.1016/j.idc.2019.10.003. Epub 2019 Dec 10. Review.

PMID:
31836330
4.

Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia.

Albin OR, Henig O, Patel TS, Valley TS, Pogue JM, Petty LA, Mills JP, Brancaccio A, Martin ET, Kaye KS.

Clin Infect Dis. 2019 Dec 13. pii: ciz1187. doi: 10.1093/cid/ciz1187. [Epub ahead of print]

PMID:
31832641
5.
6.

The devil is in the details: Factors influencing hand hygiene adherence and contamination with antibiotic-resistant organisms among healthcare providers in nursing facilities.

Mills JP, Zhu Z, Mantey J, Hatt S, Patel P, Kaye KS, Gibson K, Cassone M, Lansing B, Mody L.

Infect Control Hosp Epidemiol. 2019 Dec;40(12):1394-1399. doi: 10.1017/ice.2019.292. Epub 2019 Oct 24.

PMID:
31647042
7.

Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia?

Kaye KS, Patel T, Drusano G.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e01725-19. doi: 10.1128/AAC.01725-19. Print 2019 Nov. No abstract available.

PMID:
31640979
8.

Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa.

Lin YW, Han ML, Zhao J, Zhu Y, Rao G, Forrest A, Song J, Kaye KS, Hertzog P, Purcell A, Creek D, Zhou QT, Velkov T, Li J.

Front Pharmacol. 2019 Oct 3;10:1146. doi: 10.3389/fphar.2019.01146. eCollection 2019.

9.

Primary cytomegalovirus infection with invasive disease in a patient with inflammatory bowel disease.

Gong J, Meyerowitz EA, Isidro RA, Kaye KM.

BMJ Case Rep. 2019 Sep 30;12(9). pii: e230056. doi: 10.1136/bcr-2019-230056.

PMID:
31570344
10.

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa.

Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F.

Clin Infect Dis. 2019 Sep 23. pii: ciz816. doi: 10.1093/cid/ciz816. [Epub ahead of print]

PMID:
31545346
11.

Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients.

Petty LA, Vaughn VM, Flanders SA, Malani AN, Conlon A, Kaye KS, Thyagarajan R, Osterholzer D, Nielsen D, Eschenauer GA, Bloemers S, McLaughlin E, Gandhi TN.

JAMA Intern Med. 2019 Aug 26. doi: 10.1001/jamainternmed.2019.2871. [Epub ahead of print]

PMID:
31449295
12.

Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

Trinh TD, Jorgensen SCJ, Zasowski EJ, Claeys KC, Lagnf AM, Estrada SJ, Delaportes DJ, Huang V, Klinker KP, Kaye KS, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e01007-19. doi: 10.1128/AAC.01007-19. Print 2019 Nov.

PMID:
31405859
13.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A.

Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]

PMID:
31400759
14.

Heterogeneities in Cognitive and Socio-Emotional Development in Children With Autism Spectrum Disorder and Severe Intellectual Disability as a Comorbidity.

Bernard Paulais MA, Mazetto C, Thiébaut E, Nassif MC, Costa Coelho De Souza MT, Stefani AP, Blanc R, Gattegno MP, Aïad F, Sam N, Belal L, Fekih L, Kaye K, Contejean Y, Wendland J, Barthélémy C, Bonnet-Brilhault F, Adrien JL.

Front Psychiatry. 2019 Jul 19;10:508. doi: 10.3389/fpsyt.2019.00508. eCollection 2019.

15.

Use of Colistin in Critically Ill Patients.

Marchaim D, Kaye D, Kaye KS.

Adv Exp Med Biol. 2019;1145:155-179. doi: 10.1007/978-3-030-16373-0_12. Review.

PMID:
31364078
16.

Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in Michigan.

Henig O, Rojas LJ, Bachman MA, Rudin SD, Brennan BM, Soehnlen MK, Jones KL, Mills JP, Dombecki CR, Valyko AM, Marshall SH, Bonomo RA, Kaye KS, Washer L.

Infect Control Hosp Epidemiol. 2019 Sep;40(9):1059-1062. doi: 10.1017/ice.2019.177. Epub 2019 Jul 15.

PMID:
31303191
17.

Risk factors for endemic Acinetobacter Baumannii colonization: A case-case study.

Thorne A, Luo T, Durairajan NK, Kaye KS, Foxman B.

Am J Infect Control. 2019 Nov;47(11):1294-1297. doi: 10.1016/j.ajic.2019.04.179. Epub 2019 Jun 26.

PMID:
31253551
18.

Influence of Age, Sex, and Body Mass Index on the Thickness of the Gluteal Subcutaneous Fat: Implications for Safe Buttock Augmentation Procedures.

Frank K, Casabona G, Gotkin RH, Kaye KO, Lorenc PZ, Schenck TL, Lachman N, Green JB, Duran-Vega H, Cotofana S.

Plast Reconstr Surg. 2019 Jul;144(1):83-92. doi: 10.1097/PRS.0000000000005707.

PMID:
31246807
19.

The Pitt Bacteremia Score Predicts Mortality in Non-Bacteremic Infections.

Henderson H, Luterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Evans S, Fowler VG, Bonomo RA, Harris A, Napravnik S, van Duin D.

Clin Infect Dis. 2019 Jun 19. pii: ciz528. doi: 10.1093/cid/ciz528. [Epub ahead of print]

PMID:
31219148
20.

Influences of Age, Gender, and Body Mass Index on the Thickness of the Abdominal Fatty Layers and its Relevance for Abdominal Liposuction and Abdominoplasty.

Frank K, Hamade H, Casabona G, Gotkin RH, Kaye KO, Tiryaki T, Freytag DL, Bialowas C, Koban KC, Cotofana S.

Aesthet Surg J. 2019 Sep 13;39(10):1085-1093. doi: 10.1093/asj/sjz131.

PMID:
31056694
21.

Vancomycin-Resistant Enterococcus Acquisition in a Tertiary Care Hospital: Testing the Roles of Antibiotic Use, Proton Pump Inhibitor Use, and Colonization Pressure.

Chanderraj R, Millar JA, Patel TS, Read AF, Washer L, Kaye KS, Woods RJ.

Open Forum Infect Dis. 2019 Mar 15;6(4):ofz139. doi: 10.1093/ofid/ofz139. eCollection 2019 Apr.

22.

Implementation and Impact of an Antimicrobial Stewardship Program at a Tertiary Care Center in South India.

Singh S, Menon VP, Mohamed ZU, Kumar VA, Nampoothiri V, Sudhir S, Moni M, Dipu TS, Dutt A, Edathadathil F, Keerthivasan G, Kaye KS, Patel PK.

Open Forum Infect Dis. 2018 Nov 8;6(4):ofy290. doi: 10.1093/ofid/ofy290. eCollection 2019 Apr.

23.

Shifting Gears: The Future of Polymyxin Antibiotics.

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.

Antibiotics (Basel). 2019 Apr 12;8(2). pii: E42. doi: 10.3390/antibiotics8020042. Review.

24.

Influence of Age, Gender and Body Mass Index on the Thickness of the Gluteal Subcutaneous Fat - Implications for Safe Buttock Augmentation Procedures.

Frank K, Casabona G, Gotkin RH, Kaye KO, Lorenc ZP, Schenck TL, Lachman N, Jeremy GB, Duran-Vega H, Cotofana S.

Plast Reconstr Surg. 2019 Apr 9. doi: 10.1097/PRS.0000000000005707. [Epub ahead of print]

PMID:
30998660
25.

Multidrug-resistant Organisms in Hospitals: What Is on Patient Hands and in Their Rooms?

Mody L, Washer LL, Kaye KS, Gibson K, Saint S, Reyes K, Cassone M, Mantey J, Cao J, Altamimi S, Perri M, Sax H, Chopra V, Zervos M.

Clin Infect Dis. 2019 Nov 13;69(11):1837-1844. doi: 10.1093/cid/ciz092.

26.

Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.

Kaye KS, Petty LA, Shorr AF, Zilberberg MD.

Clin Infect Dis. 2019 Apr 8;68(Suppl 3):S193-S199. doi: 10.1093/cid/ciz002.

27.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

28.

Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.

Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, Das AF, Skarinsky D, Eckburg PB, Ellis-Grosse EJ.

Clin Infect Dis. 2019 Nov 27;69(12):2045-2056. doi: 10.1093/cid/ciz181.

29.

NDRG1 facilitates the replication and persistence of Kaposi's sarcoma-associated herpesvirus by interacting with the DNA polymerase clamp PCNA.

Zhang F, Liang D, Lin X, Zou Z, Sun R, Wang X, Liang X, Kaye KM, Lan K.

PLoS Pathog. 2019 Feb 27;15(2):e1007628. doi: 10.1371/journal.ppat.1007628. eCollection 2019 Feb.

30.

Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.

Destache CJ, Guervil DJ, Kaye KS.

Int J Antimicrob Agents. 2019 May;53(5):644-649. doi: 10.1016/j.ijantimicag.2019.01.014. Epub 2019 Jan 31.

31.
32.

The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification.

Henig O, Cooper CC, Kaye KS, Lephart P, Salimnia H, Taylor M, Hussain N, Hussain Z, Deeds K, Hayat U, Patel J, Pogue JM.

J Antimicrob Chemother. 2019 Jan 1;74(Supplement_1):i32-i39. doi: 10.1093/jac/dky533.

33.

The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Luterbach CL, Boshe A, Henderson HI, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Hujer AM, Hujer KM, Rudin SD, Domitrovic TN, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, van Duin D.

Open Forum Infect Dis. 2018 Dec 14;6(1):ofy351. doi: 10.1093/ofid/ofy351. eCollection 2019 Jan.

34.

Kaposi's Sarcoma-Associated Herpesvirus LANA-Adjacent Regions with Distinct Functions in Episome Segregation or Maintenance.

Juillard F, De León Vázquez E, Tan M, Li S, Kaye KM.

J Virol. 2019 Mar 5;93(6). pii: e02158-18. doi: 10.1128/JVI.02158-18. Print 2019 Mar 15.

35.

The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative Bacilli.

Henig O, Kaye KS, Chandramohan S, Cooper CC, Lephart P, Salimnia H, Taylor M, Pogue JM.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01477-18. doi: 10.1128/AAC.01477-18. Print 2019 Mar.

36.

Six years of experience using an advanced algorithm for botulinum toxin application.

Casabona G, Kaye K, Barreto Marchese P, Boggio R, Cotofana S.

J Cosmet Dermatol. 2019 Feb;18(1):21-35. doi: 10.1111/jocd.12815. Epub 2018 Dec 10.

PMID:
30536548
37.

Training infection prevention leaders for the present and future: United in patient safety.

Kaye KS, Haas J.

Am J Infect Control. 2018 Dec;46(12):1320-1321. doi: 10.1016/j.ajic.2018.08.023. No abstract available.

PMID:
30502755
38.

It is time to define antimicrobial never events.

Liu J, Kaye KS, Mercuro NJ, Davis SL, Patel TS, Petty LA, Pais GM, Scheetz MH.

Infect Control Hosp Epidemiol. 2019 Feb;40(2):206-207. doi: 10.1017/ice.2018.313. Epub 2018 Dec 5.

PMID:
30516126
39.

PACAP increases Arc/Arg 3.1 expression within the extended amygdala after fear conditioning in rats.

Meloni EG, Kaye KT, Venkataraman A, Carlezon WA Jr.

Neurobiol Learn Mem. 2019 Jan;157:24-34. doi: 10.1016/j.nlm.2018.11.011. Epub 2018 Nov 17.

40.

An update on antimicrobial resistance and the role of newer antimicrobial agents for Pseudomonas aeruginosa.

Pragasam AK, Veeraraghavan B, Nalini E, Anandan S, Kaye KS.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):303-316. doi: 10.4103/ijmm.IJMM_18_334. Review.

41.

Pseudomonas aeruginosa - Difficult to outmanoeuvre.

Patel PK, Patel TS, Kaye KS.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):301-302. doi: 10.4103/ijmm.IJMM_18_331. No abstract available.

42.

Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.

Henig O, Pogue JM, Cha R, Kilgore PE, Hayat U, Ja'ara M, Ali RM, Mahboob S, Pansare R, Deeds K, Joarder B, Kandala H, Dhar S, Kaye KS.

Open Forum Infect Dis. 2018 Sep 27;5(11):ofy245. doi: 10.1093/ofid/ofy245. eCollection 2018 Nov.

43.

Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.

Almangour TA, Perry GK, Terriff CM, Alhifany AA, Kaye KS.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):213-218. doi: 10.1016/j.diagmicrobio.2018.10.007. Epub 2018 Oct 16.

PMID:
30396697
44.

Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.

Albin OR, Patel TS, Kaye KS.

Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5. Review.

PMID:
30372359
45.

Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital.

Chopra T, Rivard C, Awali RA, Krishna A, Bonomo RA, Perez F, Kaye KS.

Open Forum Infect Dis. 2018 Oct 3;5(10):ofy224. doi: 10.1093/ofid/ofy224. eCollection 2018 Oct.

46.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

47.

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae.

Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS.

Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Review.

48.

In Vivo Persistence of Chimeric Virus after Substitution of the Kaposi's Sarcoma-Associated Herpesvirus LANA DNA Binding Domain with That of Murid Herpesvirus 4.

Pires de Miranda M, Quendera AP, McVey CE, Kaye KM, Simas JP.

J Virol. 2018 Oct 12;92(21). pii: e01251-18. doi: 10.1128/JVI.01251-18. Print 2018 Nov 1.

49.

The epidemiological impact and significance of carbapenem resistance in Pseudomonas aeruginosa bloodstream infections: a matched case-case-control analysis.

Aviv T, Lazarovitch T, Katz D, Zaidenstein R, Dadon M, Daniel C, Tal-Jasper R, Kaye KS, Marchaim D.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1262-1265. doi: 10.1017/ice.2018.181. Epub 2018 Aug 14.

PMID:
30103833
50.

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.

Pogue JM, Bonomo RA, Kaye KS.

Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576.

PMID:
30020449

Supplemental Content

Support Center